Gilead completes Arcellx acquisition ahead of anito-cel launch

Gilead completed its acquisition of Arcellx on April 28, 2026, so it now owns anito-cel outright. The closing paid $115 per share in cash, about $7.8 billion in implied equity value, with the $5 per share CVR still pending. The FDA action date for anito-cel is December 23, 2026.

• Completed April 28, 2026
• $115 per share in cash; implied equity value about $7.8 billion at closing
• One non-transferable $5 CVR per share, payable at $6.0 billion cumulative anito-cel sales through 2029
• Anito-cel FDA action date December 23, 2026